BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 32978015)

  • 21. Decreased serum carbohydrate antigen 19-9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma: a multicenter case-control study of 240 patients.
    Aoki S; Motoi F; Murakami Y; Sho M; Satoi S; Honda G; Uemura K; Okada KI; Matsumoto I; Nagai M; Yanagimoto H; Kurata M; Fukumoto T; Mizuma M; Yamaue H; Unno M;
    BMC Cancer; 2019 Mar; 19(1):252. PubMed ID: 30898101
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Normalization of CA19-9 following resection for pancreatic ductal adenocarcinoma is not tantamount to being cured?
    Chen T; Zhang MG; Yu XJ; Liu L
    Asian Pac J Cancer Prev; 2015; 16(2):661-6. PubMed ID: 25684504
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CA19-9 on Postoperative Surveillance in Pancreatic Ductal Adenocarcinoma: Predicting Recurrence and Changing Prognosis over Time.
    Rieser CJ; Zenati M; Hamad A; Al Abbas AI; Bahary N; Zureikat AH; Zeh HJ; Hogg ME
    Ann Surg Oncol; 2018 Nov; 25(12):3483-3491. PubMed ID: 29786131
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prediction of early recurrence of pancreatic ductal adenocarcinoma after resection.
    Sugawara T; Ban D; Nishino J; Watanabe S; Maekawa A; Ishikawa Y; Akahoshi K; Ogawa K; Ono H; Kudo A; Tanaka S; Tanabe M
    PLoS One; 2021; 16(4):e0249885. PubMed ID: 33844700
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic factors for actual long-term survival in the era of multidisciplinary treatment for pancreatic ductal adenocarcinoma.
    Nakagawa K; Akahori T; Nishiwada S; Nagai M; Nakamura K; Tanaka T; Tamamoto T; Ohbayashi C; Hasegawa M; Kichikawa K; Ikeda N; Sho M
    Langenbecks Arch Surg; 2018 Sep; 403(6):693-700. PubMed ID: 30218193
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preoperative neutrophil-to-lymphocyte ratio as a prognosticator in early stage pancreatic ductal adenocarcinoma.
    Abe T; Amano H; Kobayashi T; Hanada K; Nakahara M; Ohdan H; Noriyuki T
    Eur J Surg Oncol; 2018 Oct; 44(10):1573-1579. PubMed ID: 29807728
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CA19-9 level determines therapeutic modality in pancreatic cancer patients with para-aortic lymph node metastasis.
    Asaoka T; Miyamoto A; Maeda S; Hama N; Tsujie M; Ikeda M; Sekimoto M; Nakamori S
    Hepatobiliary Pancreat Dis Int; 2018 Feb; 17(1):75-80. PubMed ID: 29428109
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictive Early Recurrence Factors of Preoperative Clinicophysiological Findings in Pancreatic Cancer.
    Suzuki S; Shimoda M; Shimazaki J; Maruyama T; Oshiro Y; Nishida K; Sahara Y; Nagakawa Y; Tsuchida A
    Eur Surg Res; 2018; 59(5-6):329-338. PubMed ID: 30453288
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationship between autophagy and perineural invasion, clinicopathological features, and prognosis in pancreatic cancer.
    Yang YH; Liu JB; Gui Y; Lei LL; Zhang SJ
    World J Gastroenterol; 2017 Oct; 23(40):7232-7241. PubMed ID: 29142470
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic significance of preoperative PNI and CA19-9 for pancreatic ductal adenocarcinoma: A multi-institutional retrospective study.
    Itoh S; Tsujita E; Fukuzawa K; Sugimachi K; Iguchi T; Ninomiya M; Maeda T; Kajiyama K; Adachi E; Uchiyama H; Utsunomiya T; Ikeda Y; Maekawa S; Toshima T; Harada N; Yoshizumi T; Mori M
    Pancreatology; 2021 Oct; 21(7):1356-1363. PubMed ID: 34426076
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The preoperative controlling nutritional status (CONUT) score is an independent prognostic marker for pancreatic ductal adenocarcinoma.
    Terasaki F; Sugiura T; Okamura Y; Ito T; Yamamoto Y; Ashida R; Ohgi K; Uesaka K
    Updates Surg; 2021 Feb; 73(1):251-259. PubMed ID: 32410163
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognosis of malignant intraductal papillary mucinous tumours of the pancreas after surgical resection. Comparison with pancreatic ductal adenocarcinoma.
    Maire F; Hammel P; Terris B; Paye F; Scoazec JY; Cellier C; Barthet M; O'Toole D; Rufat P; Partensky C; Cuillerier E; Lévy P; Belghiti J; Ruszniewski P
    Gut; 2002 Nov; 51(5):717-22. PubMed ID: 12377813
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A nomogram based on preoperative inflammatory markers predicting the overall survival of pancreatic ductal adenocarcinoma.
    Xu J; Shi KQ; Chen BC; Huang ZP; Lu FY; Zhou MT
    J Gastroenterol Hepatol; 2017 Jul; 32(7):1394-1402. PubMed ID: 27973703
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The prognostic evaluation of CA19-9, D-dimer and TNFAIP3/A20 in patients with pancreatic ductal adenocarcinoma.
    Xu P; Wang X; Qian J; Li Z; Yao J; Xu A
    Medicine (Baltimore); 2021 Feb; 100(6):e24651. PubMed ID: 33578593
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic significance of preoperative lymphocytes, albumin, and neutrophils (LANR) index in resectable pancreatic ductal adenocarcinoma.
    Zhuang J; Wang S; Wang Y; Wu Y; Hu R
    BMC Cancer; 2024 May; 24(1):568. PubMed ID: 38714979
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A preoperative risk model for early recurrence after radical resection may facilitate initial treatment decisions concerning the use of neoadjuvant therapy for patients with pancreatic ductal adenocarcinoma.
    Guo SW; Shen J; Gao JH; Shi XH; Gao SZ; Wang H; Li B; Yuan WL; Lin L; Jin G
    Surgery; 2020 Dec; 168(6):1003-1014. PubMed ID: 32321665
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic impact of the combination of the neutrophil-to-lymphocyte ratio and serum carbohydrate antigen 19-9 in patients with pancreas head cancer.
    Kim WJ; Lim TW; Park PJ; Choi SB; Kim WB
    ANZ J Surg; 2019 Jul; 89(7-8):E302-E307. PubMed ID: 30895709
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cancer outcomes are independent of preoperative CA 19-9 in anatomically resectable pancreatic ductal adenocarcinoma: A retrospective cohort analysis.
    Kim JK; DePeralta DK; Ogami T; Denbo JW; Pimiento J; Hodul PJ; Malafa MP; Kim DW; Fleming JB; Powers BD
    J Surg Oncol; 2020 Nov; 122(6):1074-1083. PubMed ID: 32673436
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High expression of delta-like ligand 4 predicts poor prognosis after curative resection for pancreatic cancer.
    Chen HT; Cai QC; Zheng JM; Man XH; Jiang H; Song B; Jin G; Zhu W; Li ZS
    Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S464-74. PubMed ID: 21822553
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic factors affecting survival after pancreaticoduodenectomy for pancreatic adenocarcinoma (single center experience).
    El Nakeeb A; El Shobary M; El Dosoky M; Nabeh A; El Sorogy M; El Eneen AA; abu Zeid M; Elwahab MA
    Hepatogastroenterology; 2014; 61(133):1426-38. PubMed ID: 25436321
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.